Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

M. B. Urowitz, D. D. Gladman, D. Ibañez, P. R. Fortin, S. C. Bae, C. Gordon, A. Clarke, S. Bernatsky, J. G. Hanly, D. Isenberg, A. Rahman, J. Sanchez-Guerrero, D. J. Wallace, E. Ginzler, G. S. Alarcón, J. T. Merrill, I. N. Bruce, G. Sturfelt, O. Nived, K. Steinsson & 11 others M. Khamashta, Michelle Petri, S. Manzi, R. Ramsey-Goldman, M. A. Dooley, R. F. Van Vollenhoven, M. Ramos, T. Stoll, A. Zoma, K. Kalunian, C. Aranow

Research output: Contribution to journalArticle

Abstract

Objective. We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. Methods. The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. Results. Of the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. Conclusion. Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period.

Original languageEnglish (US)
Pages (from-to)132-137
Number of pages6
JournalArthritis Care and Research
Volume64
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Systemic Lupus Erythematosus
Antinuclear Antibodies
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Hispanic Americans
African Americans
Autoantibodies
Linear Models
Antibodies
DNA
Research
Population

ASJC Scopus subject areas

  • Rheumatology

Cite this

Urowitz, M. B., Gladman, D. D., Ibañez, D., Fortin, P. R., Bae, S. C., Gordon, C., ... Aranow, C. (2012). Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care and Research, 64(1), 132-137. https://doi.org/10.1002/acr.20648

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. / Urowitz, M. B.; Gladman, D. D.; Ibañez, D.; Fortin, P. R.; Bae, S. C.; Gordon, C.; Clarke, A.; Bernatsky, S.; Hanly, J. G.; Isenberg, D.; Rahman, A.; Sanchez-Guerrero, J.; Wallace, D. J.; Ginzler, E.; Alarcón, G. S.; Merrill, J. T.; Bruce, I. N.; Sturfelt, G.; Nived, O.; Steinsson, K.; Khamashta, M.; Petri, Michelle; Manzi, S.; Ramsey-Goldman, R.; Dooley, M. A.; Van Vollenhoven, R. F.; Ramos, M.; Stoll, T.; Zoma, A.; Kalunian, K.; Aranow, C.

In: Arthritis Care and Research, Vol. 64, No. 1, 01.2012, p. 132-137.

Research output: Contribution to journalArticle

Urowitz, MB, Gladman, DD, Ibañez, D, Fortin, PR, Bae, SC, Gordon, C, Clarke, A, Bernatsky, S, Hanly, JG, Isenberg, D, Rahman, A, Sanchez-Guerrero, J, Wallace, DJ, Ginzler, E, Alarcón, GS, Merrill, JT, Bruce, IN, Sturfelt, G, Nived, O, Steinsson, K, Khamashta, M, Petri, M, Manzi, S, Ramsey-Goldman, R, Dooley, MA, Van Vollenhoven, RF, Ramos, M, Stoll, T, Zoma, A, Kalunian, K & Aranow, C 2012, 'Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort', Arthritis Care and Research, vol. 64, no. 1, pp. 132-137. https://doi.org/10.1002/acr.20648
Urowitz, M. B. ; Gladman, D. D. ; Ibañez, D. ; Fortin, P. R. ; Bae, S. C. ; Gordon, C. ; Clarke, A. ; Bernatsky, S. ; Hanly, J. G. ; Isenberg, D. ; Rahman, A. ; Sanchez-Guerrero, J. ; Wallace, D. J. ; Ginzler, E. ; Alarcón, G. S. ; Merrill, J. T. ; Bruce, I. N. ; Sturfelt, G. ; Nived, O. ; Steinsson, K. ; Khamashta, M. ; Petri, Michelle ; Manzi, S. ; Ramsey-Goldman, R. ; Dooley, M. A. ; Van Vollenhoven, R. F. ; Ramos, M. ; Stoll, T. ; Zoma, A. ; Kalunian, K. ; Aranow, C. / Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. In: Arthritis Care and Research. 2012 ; Vol. 64, No. 1. pp. 132-137.
@article{33de4933bde54ddcaab95a3a66d3d413,
title = "Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort",
abstract = "Objective. We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. Methods. The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. Results. Of the 298 patients, 87{\%} were women, 55{\%} were white, 12{\%} were African American, 14{\%} were Asian, 16{\%} were Hispanic, and 2{\%} were categorized as {"}other.{"} At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. Conclusion. Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period.",
author = "Urowitz, {M. B.} and Gladman, {D. D.} and D. Iba{\~n}ez and Fortin, {P. R.} and Bae, {S. C.} and C. Gordon and A. Clarke and S. Bernatsky and Hanly, {J. G.} and D. Isenberg and A. Rahman and J. Sanchez-Guerrero and Wallace, {D. J.} and E. Ginzler and Alarc{\'o}n, {G. S.} and Merrill, {J. T.} and Bruce, {I. N.} and G. Sturfelt and O. Nived and K. Steinsson and M. Khamashta and Michelle Petri and S. Manzi and R. Ramsey-Goldman and Dooley, {M. A.} and {Van Vollenhoven}, {R. F.} and M. Ramos and T. Stoll and A. Zoma and K. Kalunian and C. Aranow",
year = "2012",
month = "1",
doi = "10.1002/acr.20648",
language = "English (US)",
volume = "64",
pages = "132--137",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

AU - Urowitz, M. B.

AU - Gladman, D. D.

AU - Ibañez, D.

AU - Fortin, P. R.

AU - Bae, S. C.

AU - Gordon, C.

AU - Clarke, A.

AU - Bernatsky, S.

AU - Hanly, J. G.

AU - Isenberg, D.

AU - Rahman, A.

AU - Sanchez-Guerrero, J.

AU - Wallace, D. J.

AU - Ginzler, E.

AU - Alarcón, G. S.

AU - Merrill, J. T.

AU - Bruce, I. N.

AU - Sturfelt, G.

AU - Nived, O.

AU - Steinsson, K.

AU - Khamashta, M.

AU - Petri, Michelle

AU - Manzi, S.

AU - Ramsey-Goldman, R.

AU - Dooley, M. A.

AU - Van Vollenhoven, R. F.

AU - Ramos, M.

AU - Stoll, T.

AU - Zoma, A.

AU - Kalunian, K.

AU - Aranow, C.

PY - 2012/1

Y1 - 2012/1

N2 - Objective. We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. Methods. The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. Results. Of the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. Conclusion. Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period.

AB - Objective. We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. Methods. The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. Results. Of the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. Conclusion. Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period.

UR - http://www.scopus.com/inward/record.url?scp=84856866632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856866632&partnerID=8YFLogxK

U2 - 10.1002/acr.20648

DO - 10.1002/acr.20648

M3 - Article

VL - 64

SP - 132

EP - 137

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -